TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Michela CortesiMichele ZanoniRoberta MaltoniSara RavaioliMaria Maddalena TumedeiFrancesca PiriniSara BravacciniPublished in: Expert opinion on therapeutic targets (2022)
ADCs targeting Trop2 recently received an accelerated FDA approval for the therapy of metastatic TNBC. The prospects for these novel ADCs in BC subtypes other than TNBC are discussed, taking into account the main pitfalls relative to Trop2 structure and function.